Hemic and Lymphatic Diseases

593 trials 238 recruiting

Filter these 593 trials by phase, country and sponsor.

Open in Search →

Study to Assess the Effect of Food on the Pharmacokinetics of CA-4948 in Healthy Male Subjects Ended

2023-509691-41-00 Hematologic malignancies 3 2024-03-14
A first-in-human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy in subjects with relapsed/refractory Acute Myeloid Leukemia or M… Ended

2023-507321-42-00 Myelodysplastic syndrome (MDS) 1 2024-02-15
A Global, Open-label Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Hemophilia B With Inhibitors (PRESent-3) Ended

2022-502881-25-00 Hemophilia B 4 2023-11-16
A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moder… Ended

2022-502880-39-00 Severe Hemophilia A or Moderately Severe to Severe Hemo 4 2023-11-13
A Study to Evaluate CC-486 in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Cancer Partic… Ended

2023-503427-26-00 Myeloid malignancies with moderate or severe hepatic im 3 2023-11-10
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPA… Ended

2023-503830-27-00 Large B-Cell Lymphoma (LBCL) 4 2023-10-17
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA2) Ended

2022-501927-25-00 Large B-Cell Lymphoma (LBCL) 4 2023-09-29
A Study Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso‑O… Ended

2022-502546-26-00 Sickle Cell Disease 3 2023-09-11
APTIVATE Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with… Ended

2023-503244-14-00 Relapsed or Refractory Acute Myeloid Leukemia (AML) 7 2023-08-11
An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa Ended

2022-502921-16-00 Hemophilia A and B 6 2023-07-21
Pharmacokinetics of anti-lymphocyte serum in the prevention of GvHD in children and adults receiving allogeneic hematopoietic stem cell tran… Ended

2022-501594-39-00 pediatric and adult patients undergoing HSC allograft p 6 2023-07-17
A trial to learn how well REGN9933 works for preventing blood clots after knee replacement surgery in adult participants Ended

2022-501470-18-00 Thromboembolic disease 4 2023-06-26
Bioequivalence of Eltrombopag 75 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions Ended

2022-502701-15-00 Thrombocytopenia 2 2023-06-07
Bioequivalence of Eltrombopag 75 mg Film-Coated Tablets in Healthy Subjects Under Fed Conditions. Ended

2022-502702-32-00 Aplastic anemia 2 2023-05-30
A Phase 2b study of TAK-755 (rADAMTS13) with minimal to no plasma exchange in the treatment of patients with thrombotic thrombocytopenic Pur… Ended

2023-507787-39-00 Immune-mediated thrombotic thrombocytopenic purpura (iT 4 2023-04-27
Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (AZURE) Ended

2023-510144-20-00 Advanced Systemic Mastocytosis 9 2023-03-29
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07
Aspirin in immune thrombocytopenia patients with cardiovascular disease Ended

2024-513846-13-00 Immune thRombocytopenia 11 2023-01-16
Cardiac safety of treosulfan chemotherapy prior to stem cell transplantation in patients with leukemia. Ended

2024-517377-24-00 Subjects with AML ( Acute myeloid leukaemia) or MDS (My 3 2022-12-20
Caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombo… Ended

2024-513262-19-00 Thrombotic Thrombocytopenic Purpura 5 2022-11-21
A long-term study to evaluate if KVD900 is safe and effective in treating attacks in patients with Hereditary Angioedema. Ended

2023-505904-41-00 Hereditary Angioedema Type I or II 5 2022-11-17
A trial to learn if REGN7999 is safe and well tolerated, and how it works in the body of healthy participants. Ended

2022-500398-15-00 Healthy - R7999 being developed for the treatment of d 1 2022-10-24
A Phase 3 safety study of BAY 94-9027 in children 7 to <12 years of age with severe hemophilia A Ended

2023-504388-18-00 Severe hemophilia A (<1% FVIII:C) 5 2022-09-26
A clinical study conducted to evaluate the safety, efficacy and tolerability of a drug called liposomal annamycin administered with cytarabi… Ended

2024-516388-10-00 Acute Myeloid Leukemia 9 2022-09-23